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Multiple sclerosis (MS)  is an  inflammatory and demyelization disease of the central nervous system  (SNC). MS affects more than 2 millions of people, which a major rate 
among women  (3:1). Clinical manifestation begins,  in most cases, in the third or  fourth decade of  life. The patients have neurological deficits that exhibit a relapsing and 
remitting pattern. 
There  are  four  main  pathological  features  in  MS:  (1)  inflammation,  which  is  believed  to  have  an  important  role  in  CNS  tissue  damage  in  the  majority  of  cases;  (2) 
demyelination, the hallmark of MS, where the myelin sheath or the oligodendrocyte  is destroyed by the  inflammatory process;  (3) axonal  loss or damage; and  (4) gliosis 
(astrocytic reaction to CNS damage)
Figure 2. Schematic diagram of some of the key pathological features of EAE pathogenesis. 
Adapted  of  CS.  Constantinescu,  et  al. Experimental  autoimmune  encephalomyelitis  (EAE)  as  a model  for multiple 
sclerosis (MS). British Journal of Pharmacology 164 (2011) 1079‐1106.Figure 1. Subtypes of MS depending on the clinical course
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Figure 3. Different induction pathways to develop the 
disease in animal models. EAE can be induced by active 
or passive induction. 
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Figure 5. Treatment EAE vs MS: Success and discrepancies
CONCLUSIONS
Ms is a neurodegenerative disease that affects a lot 
people around the world, but we haven’t found yet a 
treatment for it 
In spite of all this models,  it is still investigating to find 
a better animal model, which resembles more closely 
MS. If we can achieve this model, we may get more 
efficiency in the experiments and also is more probable 
that more treatments reach clinical trials. Maybe if we 
continue studying and improving animal models, in 
some years we will have a treatment for MS.
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